timothy sykes logo
Moderna’s Groundbreaking Combo Drug Trials with Merck Thumbnail
ADD US ONG Google News

Moderna’s Groundbreaking Combo Drug Trials with Merck

ELLIS HOBBS•UPDATED JAN. 21, 2026, 5:03 PM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

Moderna Inc.’s stocks have been trading up by 22.88 percent amid investor enthusiasm driven by promising new vaccine developments.

  • Remarkable stock price surge by 17% underscores confidence in Moderna’s revenue projection that aligns with the top of its guidance for 2025, fostering investor optimism.

  • European Patent Office’s decision to negate an Arbutus Biopharma technology patent symbolizes a win for Moderna, lessening potential financial liabilities from significant legal threats.

  • Collaborations between Moderna and Merck continue yielding fruit, as evidenced by positive five-year follow-up data for their experimental drug, showcasing considerable cancer recurrence reduction.

  • Citi analysts recognize the invalidation of Arbutus Biopharma’s patent as bolstering Moderna’s position in Europe, potentially lowering royalty obligations and enhancing the firm’s competitive edge.

Candlestick Chart

Live Update At 17:03:25 EST: On Wednesday, January 21, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 22.88%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview:

The latest earnings data portrays Moderna in an intriguing light. With operating revenues hitting a striking $1.016B (B for billion), the narrative takes a twist with the net income showing a stark loss of $200M. This earnings dip indicates a temporary hurdle in an otherwise strategic gameplay by the company. Strategy plays center stage as they reveal a keen focus on managing expenses and steering towards cost-efficient practices. A reasonable reduction in anticipated operating expenses to a predicted range between $4.2B – $4.6B by 2027 fuels their vision for cash breakeven by 2028.

Stock price starting on $43.5, the market reacted positively with a closing at $49.81, indicating a significant uptick in investor confidence. This period of forecasted revenue growth and strategic partnerships shines a luminaire on the company’s altruistic goals. However, Moderna’s advantage stems not just from today’s stock market movement or tomorrow’s revenue potentials, but in paving pathways to accessible healthcare innovations grounded in evolving technological breakthroughs.

Market Reaction to Recent Developments:

Positive development has led investors to recalibrate their perceptions, demonstrating a faith built upon tangible, collaborative success, as seen in the Moderna-Merck alliance. News of Arbutus Biopharma’s patent invalidation further secures Moderna’s European aspirations, echoing investor sentiments into rising stock prices and fostering an optimistic outlook for fiscal performance.

More Breaking News

Conclusion:

The synergy between strategic alliances and financial prudence continues to fuel Moderna’s journey. Amid uncertainties, the company’s unwavering commitment to innovative solutions, armed with favorable regulatory decisions and advancing trial outcomes, ensures it retains its favorable industry position. As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.” This principle echoes in Moderna’s adaptive strategies as it navigates complex market conditions. As Moderna innovates and diversifies its portfolio, the market watches closely, expecting both progressive healthcare solutions and sustained financial robustness, beckoning a promising horizon.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading MRNA

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”